Abstract 18950: PCSK9 and LDL-C Lowering Effect of SCAP Targeting siRNA in Mouse and Non-Human Primate Models
Kristian K. Jensen(University of Copenhagen), Shirly Pinto(Cornell University), Dan Xie(Sun Yat-sen University), Gail Forrest(Merck & Co., Inc., Rahway, NJ, USA (United States)), James Hubert, Stephen F. Previs(Howard Hughes Medical Institute), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Marija Tadin‐Strapps, Daphne Szeto(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stephanie Williams(United States Military Academy), Kithsiri Herath(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ray Rosa(Merck & Co., Inc., Rahway, NJ, USA (United States)), Haihong Zhou, Sheng-Ping Wang(Merck & Co., Inc., Rahway, NJ, USA (United States)), David G. McLaren(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yanqing Kan(Merck & Co., Inc., Rahway, NJ, USA (United States))
Circulation
November 25, 2014
Cited by 0
Related Papers
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
Total Synthesis of Spirotryprostatin A, Leading to the Discovery of Some Biologically Promising Analogues
|Journal of the American Chemical Society|1999|463
Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90
|Proceedings of the National Academy of Sciences|1996|409
A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.
|PubMed|1995|385
Micro RNA 145 Targets the Insulin Receptor Substrate-1 and Inhibits the Growth of Colon Cancer Cells
|Journal of Biological Chemistry|2007|356